Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.

Medical decision making : an international journal of the Society for Medical Decision Making - 1 Jan 2000

Eckman Mark H, Singh Sushil K, Erban John K, Kao Grace

Abstract excerpt

BACKGROUND: Survivors of venous thromboembolism who have the factor V Leiden mutation have an increased risk of recurrent venous thromboembolism (VTE), but the cost-effectiveness of testing for factor VLeiden has not been assessed. METHODS: We used a Markov state transition decision model to evaluate the cost-effectiveness of factor V Leiden testing and treatment strategies in survivors of VTE using a societal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Costs and Cost Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Support Techniques

Share to Factor V

Share to Heterozygote

Share to Markov Chains

Share to Pulmonary Embolism

Share to Venous Thrombosis

Source

Identifiers

PMID: 11958494
DOI: 10.1177/0272989X0202200209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.PMID 11958494Read ↗

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.Semantic proximity Read ↗

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.Semantic proximity Read ↗

Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.Semantic proximity Read ↗

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.Semantic proximity Read ↗

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.Semantic proximity Read ↗

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.Semantic proximity Read ↗

Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations.Semantic proximity Read ↗

Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.Semantic proximity Read ↗

The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.Semantic proximity Read ↗

A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.Semantic proximity Read ↗

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.